News

Promising results for NI203, an experimental therapy depleting pathologic IAPP aggregates to protect beta cell health, published in Nature Communications.

Promising Phase 1 results for antibody NI006 in ATTR cardiomyopathy published in The New England Journal of Medicine.

Primary results of its Phase 1b proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR cardiomyopathy, will be presented in Prague at ESC Heart Failure Congress 2023, on May 20, 4:40 pm CEST.

Professor Roger M. Nitsch, Neurimmune’s CEO & President, will be presenting a keynote lecture on the “Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease” at CTAD on Friday, December 2, 9:00a.m. Pacific Time.

Neurimmune and AstraZeneca close exclusive global collaboration and license agreement to develop and commercialize NI006.

Neurimmune AG today announced the appointment of Alfred W. Sandrock, Jr., to its Board of Directors.

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases.

Neurimmune has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin.